Welcome to our dedicated page for Cognizant Technology Solutions news (Ticker: $CTSH), a resource for investors and traders seeking the latest updates and insights on Cognizant Technology Solutions stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cognizant Technology Solutions's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cognizant Technology Solutions's position in the market.
Cognizant (Nasdaq: CTSH) reported first quarter 2024 financial results with revenue of $4.8 billion, a 1.1% year-over-year decline, or 1.2% decline in constant currency. Operating margin remained flat at 14.6%, while Adjusted Operating Margin expanded to 15.1%. The company returned $284 million to shareholders through share repurchases and dividends. Revenue guidance for 2024 is unchanged at (2.0%) to 2.0% in constant currency, with Adjusted Operating Margin guidance at 15.3-15.5%.
Cognizant (Nasdaq: CTSH) has entered into a five-year strategic partnership with Telstra, aiming to enhance software engineering capabilities, drive innovation, and improve customer and employee experience. The collaboration will accelerate Telstra's speed to market, operational efficiency, and technology outcomes by leveraging modern technologies like artificial intelligence (AI).